TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15590250
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg neostigmine) with mepivacaine (100 mg)
Study: 9463302
Drug: Pectin/chamomile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin/chamomile extract preparation (Diarrhoesan)
Study: 3525428
Drug: Gabapentin 200-400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 200-400 mg
Study: 3525428
Drug: Gabapentin 100
Normalized name: gabapentin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 100 mg
Study: 3525428
Drug: Gabapentin 50-200
Normalized name: gabapentin 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 50-200 mg
Study: 16781073
Drug: Gabapentin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (various doses)
Study: 28636433
Drug: AGS‐004 dendritic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS‐004 dendritic cell therapy administered monthly after ART initiation during acute HIV infection
Study: 28636433
Drug: AGS‐004 dendritic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGS‐004 dendritic cell therapy
Study: 25185281
Drug: SIT (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (standardized allergen vaccine) for 3 years
Study: 25185281
Drug: ST (symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST (symptomatic therapy)
Study: 20728275
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of naloxone (0.02 mg/kg)
Study: 20728275
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of naloxone (0.14 mg/kg)
Study: 24447629
Drug: Ezetimibe/Simvastatin 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/Simvastatin 10/40 mg
Study: 18266852
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the statin dose
Study: 16009156
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of levonorgestrel (1.5 mg)
Study: 16009156
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of levonorgestrel (1.5 mg)
Study: 10638905
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIVA) with nicomorphine
Study: 9580247
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (RI)
Study: 12650950
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg b.i.d.
Study: 6366809
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg naproxen daily for 7 days
Study: 6366809
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g acetylsalicylic acid daily for 7 days
Study: 28840431
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no photobiomodulation therapy)
Study: 17503668
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (cART) with zidovudine/lamivudine
Study: 8814744
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir 3% ointment
Study: 1711089
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (radiation and hyperthermia with bleomycin)
Study: 6601941
Drug: Propranolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol therapy continued intraoperatively and postoperatively
Study: 6601941
Drug: Propranolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol therapy discontinued
Study: 31583748
Drug: Cognitively-Based Compassion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitively-Based Compassion Training (CBCT) administered for 20 hours across 8 to 10 weeks to parents (n = 25)
Study: 26135275
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support intervention; details on dosage and duration not available.
Study: 23638803
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant (Ozurdex)
Study: 21185347
Drug: OROS®-methylphenidate hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS®-methylphenidate hydrochloride (MPH) 18, 36 or 72 mg
Study: 19723572
Drug: Fraxinus excelsior
Normalized name: FRAXINUS EXCELSIOR LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxinus excelsior L. seed extract (1.0 g)
Study: 3544892
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg orally over three days)
Study: 3544892
Drug: Amodiaquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (25 mg/kg orally over three days)
Study: 20800193
Drug: Defocused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Defocused extracorporeal shock wave therapy (ESWT, 100 impulses/cm(2) at 0.1 mJ/mm(2)) applied once to the donor site, immediately after skin harvest
Study: 20800193
Drug: Standard topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard topical therapy (nonadherent silicone mesh and antiseptic gel) without ESWT
Study: 10736124
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) administered for 100 minutes (150 mg/kg over 1 hour followed by 14 mg/kg per hour for 40 minutes)
Study: 9369111
Drug: 2 liters
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 liters of polyethylene glycol solution combined with a laxative (Group A)
Study: 9369111
Drug: 4 liters
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 liters of polyethylene glycol solution (Group B)
Study: 9952267
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) monotherapy
Study: 3994616
Drug: dimenhydrinate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimenhydrinate (50 mg)
Study: 3994616
Drug: promethazine hydrochloride
Normalized name: Promethazine Hydrochloride
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: promethazine hydrochloride (25 mg)
Study: 3994616
Drug: mixture (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixture (25 mg promethazine plus 10 mg d-amphetamine)
Study: 3994616
Drug: promethazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine (50 mg)
Study: 30023451
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing and Cognitive Behavioural Therapy (MI-CBT) in addition to Treatment as Usual (TAU)
Study: 28701387
Drug: Moderate iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate iron status (serum ferritin 12-75 μg/L)
Study: 28701387
Drug: High iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High iron status (serum ferritin ≥75 μg/L)
Study: 28701387
Drug: High iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High iron status with normal serum soluble transferrin receptor concentration (<8.3 mg/L)
Study: 28701387
Drug: Deficient iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deficient iron status (serum ferritin <12 or <15 μg/L)
Study: 24093978
Drug: Ormeloxifene 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ormeloxifene 30 mg, twice a week for 3 months
Study: 21962052
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L O2 · min(‐1)
Study: 21962052
Drug: 3 L
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 L O2 · min(‐1)
Study: 18267048
Drug: Chlorhexidine-neomycin cream
Normalized name: chlorhexidine / neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-neomycin cream and nasal cautery
Study: 18267048
Drug: Chlorhexidine-neomycin cream
Normalized name: chlorhexidine / neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-neomycin cream alone
Study: 16894588
Drug: Treatment-resistant late-onset
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant late-onset depressive disorder
Study: 16894588
Drug: Treatment-responsive late-onset
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-responsive late-onset depressive disorder
Study: 9046503
Drug: External cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: External cooling system with bupivacaine/morphine
Study: 21123342
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention (systematic health education, intensive and individualised intervention, treatment, and rehabilitation)
Study: 15669709
Drug: One-stage procedure
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage procedure with a two-piece implant and a 3-month healing period (Group A)
Study: 15669709
Drug: Two-stage procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage procedure with a two-piece implant and a 3-month healing period (Group B - Control Group)
Study: 15669709
Drug: One-stage procedure
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage procedure with a one-piece implant and a 3-month healing period (Group C)
Study: 15669709
Drug: One-stage surgical
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage surgical procedure with a two-piece implant and early loading (within 3 weeks) (Group D)
Study: 11352436
Drug: Moxifloxacin 100mg
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 100mg twice daily
Study: 11352436
Drug: Moxifloxacin 200mg
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 200mg twice daily
Study: 23993130
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400mg once daily
Study: 11352436
Drug: Moxifloxacin 600mg
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 600mg once daily
Study: 9229034
Drug: Antimanic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimanic treatment (specifics not provided)
Study: 8105716
Drug: 0.105 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.105 mg/kg MIV (1.5 x ED95) and H1/H2 antagonist
Study: 8105716
Drug: 0.105 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.105 mg/kg MIV and placebo
Study: 8105716
Drug: 0.21 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.21 mg/kg MIV (3 x ED95) and H1/H2 antagonist
Study: 8105716
Drug: 0.21 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.21 mg/kg MIV and placebo
Study: 3145665
Drug: Cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1200 mg, q.i.d. for 4 weeks
Study: 27793166
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2b therapy at 1.5 mcg/kg for 48 weeks
Study: 27793166
Drug: HBsAg <1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg <1500 IU/mL at week 12
Study: 27793166
Drug: HBsAg decrease
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg decrease >1.5 logIU/mL at week 12
Study: 27793166
Drug: HBsAg >20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg >20,000 IU/mL at week 12
Study: 27793166
Drug: HBsAg >20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg >20,000 IU/mL at week 24
Study: 24346752
Drug: Haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 15 mg
Study: 24346752
Drug: Olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 20 mg
Study: 24346752
Drug: Risperidone 2
Normalized name: risperidone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2 to 6 mg
Study: 24188719
Drug: LINDA intervention
Normalized name: Lindane
DrugBank: Lindane (DB00431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LINDA intervention (n = 1,537) received a 20‐minute individualized lifestyle counseling session followed by further support at six‐monthly follow-ups for 1.5‐2.5 years.
Study: 18423009
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 10 mg administered at 9 p.m. for four nights
Study: 18423009
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 9 p.m. for four nights
Study: 8916314
Drug: Idarubicin (IDA)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDA) 12 mg/m2/d for 3 days and cytosine arabinoside (Ara‐C) 100 mg/m2/d for 7 days
Study: 1858985
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg IV) pretreatment before tracheal extubation
Study: 26905266
Drug: Mesalazine modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine modified-release tablets (MR group, n = 126)
Study: 26905266
Drug: Other enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other enteric-coated tablets (EC group, n = 125)
Study: 21512102
Drug: Intensive reading
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive reading intervention (50-minute daily sessions in groups of 2-4 students)
Study: 19175878
Drug: lamivudine +
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine + vaccine + HBIg
Study: 19175878
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + vaccine + HBIg
Study: 15889321
Drug: Postprandial aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial aspart insulin
Study: 15889321
Drug: Preprandial aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial aspart insulin
Study: 15889321
Drug: Both preprandial
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preprandial and postprandial aspart insulin
Study: 2666559
Drug: Non-pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological therapy (started after 1 year for G1)
Study: 2666559
Drug: Non-pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological therapy (used from the beginning for G2)
Study: 2666559
Drug: Non-pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological therapy (for both groups)
Study: 24142473
Drug: Besifloxacin ophthalmic
Normalized name: besifloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifloxacin ophthalmic suspension 0.6 %
Study: 17685683
Drug: Contrast Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast Water Therapy (CWT)
Study: 16237983
Drug: Intravascular irradiation
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular irradiation therapy
Study: 9428121
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams a day of oral acyclovir for 16 weeks after transplantation
Study: 8515787
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of vesnarinone per day
Study: 8515787
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of vesnarinone per day
Study: 31662037
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intra-arterial therapies
Study: 26079223
Drug: 1.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/d GAA
Study: 26079223
Drug: 2.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/d GAA
Study: 26079223
Drug: 4.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g/d GAA
Study: 21650082
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of perindopril erbumine 4 mg
Study: 21650082
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of perindopril erbumine 4 mg
Study: 19167636
Drug: Cibenzoline (Cib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (Cib, 70 mg)
Study: 19167636
Drug: Pilsicainide (Pil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide (Pil, 50 mg)
Study: 25317365
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg twice daily
Study: 16750796
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (including gabapentin, venlafaxine, amitriptyline)
Study: 7509573
Drug: Child-centered therapy
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-centered therapy
Study: 10806698
Drug: Oxytocin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (20 IU injected into uterine muscle and 20 IU intravenous injection immediately after delivery)
Study: 29528117
Drug: Dopamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2 μg kg-1 min-1)
Study: 26951940
Drug: Doxycycline 40‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 40‐mg modified‐release capsules
Study: 24721108
Drug: Internet-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based guided self-help intervention based on problem-solving therapy for glioma patients with depressive symptoms.
Study: 23570677
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (8 g magnesium sulphate heptahydrate in 50 ml infusion over 30 minutes)
Study: 23570677
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic sodium chloride solution 0.9% in 50 ml infusion over 30 minutes)
Study: 19308807
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical therapy (control group)
Study: 8024262
Drug: Scopolamine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (low and medium doses)
Study: 28096208
Drug: Alteplase administered
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase administered at the CT scanner
Study: 17270614
Drug: Urethral botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral botulinum A toxin (BoNT‐A) injection
Study: 15520109
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) and supplemental iron therapy
Study: 28218006
Drug: Red laser
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red laser (660 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Study: 28218006
Drug: Infrared laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared laser (790 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Study: 25708022
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg droxidopa
Study: 25708022
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg droxidopa
Study: 10081530
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene brachial plexus block with bupivacaine (1.25 mg kg‐1 + 0.25 mg kg‐1 h‐1)
Study: 10081530
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg i.m. and 2 mg i.v.)
Study: 10081530
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with morphine (bolus 1 mg)
Study: 7553233
Drug: Topical interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon-beta cream
Study: 2187327
Drug: Enteric-coated sodium
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated sodium fluoride tablets and calcium supplements
Study: 2187327
Drug: Enteric-coated sodium
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated sodium fluoride tablets and calcium supplements with vitamin D
Study: 41455
Drug: Choline chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline chloride (up to 20 g/day)
Study: 31811360
Drug: Twice-daily oral
Normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily oral iron therapy (60 mg elemental iron twice daily)
Study: 31811360
Drug: Alternate-day oral
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day oral iron therapy (120 mg iron on alternate days)
Study: 26132140
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (50 mg/day)
Study: 22004765
Drug: Tanezumab 200
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 200 μg/kg
Study: 16542198
Drug: Saquinavir soft-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir soft-gel capsules 1200 mg three times daily for 3 days
Study: 15307694
Drug: Compound Fructus
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Fructus Arctii Mixture (FAM)
Study: 11124359
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 9-methylene PGE(2) vaginal gel (meteneprost)
Study: 11124359
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg oral PGE(1) (misoprostol)
Study: 11124359
Drug: Oral PGE(1)
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral PGE(1) (misoprostol)
Study: 11124359
Drug: 9-methylene vaginal
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-methylene vaginal PGE(2) gel (meteneprost)